1-20 of 20
Hagop M. Kantarjian, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs).

Naveen Pemmaraju, M.D., Hagop M Kantarjian, M.D., Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD, Sherry A. Pierce, RN, BS, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2845.
https://doi.org/10.1182/blood.V120.21.2845.2845
Published: 2012
Journal Articles

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Steven M. Kornblau, MD, PhD, Stefan Faderl, MD, Alessandra Ferrajoli, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Elias J. Jabbour, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 3774.
https://doi.org/10.1182/blood.V120.21.3774.3774
Published: 2012
Journal Articles

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Rajyalakshmi Luthra, Ph.D., Alfonso Quintás-Cardama, M.D., Elias J. Jabbour, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Susan O'Brien, M.D., Jorge E. Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 3781.
https://doi.org/10.1182/blood.V120.21.3781.3781
Published: 2012
Journal Articles

Nomogram to Prognosticate Outcomes in Patients with Chronic Myeloid Leukemia At Any Time-Point During Tyrosine Kinase Inhibitor Therapy

Alfonso Quintás-Cardama, M.D., Xuelin Huang, PhD, Sangbum Choi, PhD, Hagop M Kantarjian, M.D., Jorge E. Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 71.
https://doi.org/10.1182/blood.V120.21.71.71
Published: 2012
Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Jorge E. Cortes, MD, Dong-Wook Kim, MD, Javier Pinilla-Ibarz, MD, PhD, Philipp le Coutre, MD, Ron Paquette, MD, PhD, Charles Chuah, MD, Franck E Nicolini, MD, PhD, Jane Apperley, H. Jean Khoury, Moshe Talpaz, MD, John F. DiPersio, MD, PhD, Daniel J. DeAngelo, MD, PhD, Elisabetta Abruzzese, Delphine Rea, MD, PhD, Michele Baccarani, MD, Martin C Muller, Carlo Gambacorti-Passerini, MD, Stephane Wong, PhD, Stephanie Lustgarten, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Francois Guilhot, MD, Michael W. Deininger, MD, PhD, Andreas Hochhaus, MD, Timothy Hughes, John M Goldman, MD, Neil Shah, MD, PhD, Hagop M Kantarjian, M.D., The PACE Study Group
Journal: Blood
Blood (2012) 120 (21): 163.
https://doi.org/10.1182/blood.V120.21.163.163
Published: 2012
Journal Articles

Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia.

Michael J. Keating, M.B., B.S., William G. Wierda, M.D., Ph.D, Constantine S. Tam, M.B., B.S., Alice Lynn, Susan O'Brien, M.D., Susan Lerner, M.S., RHIA, Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2009) 114 (22): 2381.
https://doi.org/10.1182/blood.V114.22.2381.2381
Published: 2009
Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.
Journal: Blood
Blood (2006) 108 (11): 2652.
https://doi.org/10.1182/blood.V108.11.2652.2652
Published: 2006
Journal Articles

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Analysis of 2083 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, M.D., Peter McLaughlin, M.D., Sijin Wen, M.S., William Wierda, M.D., Ph.D., Hagop M. Kantarjian, M.D., John Manning, M.D., Susan Lerner, M.S., Mark Hess, B.B.A., Emil J. Freireich, M.D., Michael J. Keating, M.D.
Journal: Blood
Blood (2006) 108 (11): 2790.
https://doi.org/10.1182/blood.V108.11.2790.2790
Published: 2006
Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.
Journal: Blood
Blood (2006) 108 (11): 2749.
https://doi.org/10.1182/blood.V108.11.2749.2749
Published: 2006
Journal Articles

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Elihu H. Estey, MD, Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2006) 108 (11): 1965.
https://doi.org/10.1182/blood.V108.11.1965.1965
Published: 2006
Journal Articles

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, M.D., Michael J. Keating, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Asa Koller, M.D., Guillermo Garcia-Manero, M.D., Sherry Pierce, B.S.N., Mark Brandt, Emil J. Freireich, M.D., Elihu H. Estey, M.D.
Journal: Blood
Blood (2006) 108 (11): 802.
https://doi.org/10.1182/blood.V108.11.802.802
Published: 2006
Journal Articles

Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Peter McLaughlin, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., William G. Wierda, M.D., Ph.D., John T. Manning, M.D., Lynne V. Abruzzo, M.D., Ph.D., Susan Lerner, M.S., Mark A. Hess, B.B.A., Hagop M. Kantarjian, M.D., Emil J. Freireich, M.D., Michael J. Keating, M.D.
Journal: Blood
Blood (2006) 108 (11): 4958.
https://doi.org/10.1182/blood.V108.11.4958.4958
Published: 2006
Journal Articles

Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).

Yasuhiro Oki, MD, Jaroslav Jelinek, M.D. Ph.D., Hagop M. Kantarjian, M.D., Jean-Pierre J. Issa, M.D.
Journal: Blood
Blood (2006) 108 (11): 2322.
https://doi.org/10.1182/blood.V108.11.2322.2322
Published: 2006
Journal Articles

Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML).

Apostolia-Maria Tsimberidou, MD, PhD, Michael J. Keating, M.D., Hagop M. Kantarjian, M.D., Susan O’Brien, M.D., Jorge Cortes, M.D., Charles Koller, M.D., BA, Francis Giles, M.D., Sherry Pierce, BSN, BA, Mark Brandt, Miloslav Beran, M.D., Ph.D., Elihu Estey, M.D.
Journal: Blood
Blood (2006) 108 (11): 2008.
https://doi.org/10.1182/blood.V108.11.2008.2008
Published: 2006
Journal Articles

Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.

Ricardo H. Alvarez, M.D., Hagop M. Kantarjian, M.D., Carlos Bueso-Ramos, M.D., PhD, Moshe Talpaz, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Mary Beth Rios, Jianqin Shan, PhD, Jorge Cortes, M.D.
Journal: Blood
Blood (2004) 104 (11): 2939.
https://doi.org/10.1182/blood.V104.11.2939.2939
Published: 2004
Journal Articles

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Jean-Pierre J. Issa, M.D., Vazganush Gharibyan, Ph.D., Jaroslav Jelinek, M.D., Ph.D., Gail Morris, RN, Srdan Verstovsek, M.D., Moshe Talpaz, M.D., Guillermo Garcia-Manero, M.D., Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 2956.
https://doi.org/10.1182/blood.V104.11.2956.2956
Published: 2004
Journal Articles

WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells.

Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Quin Van, B.S., David M. Harris, B.S., Waldemar Priebe, Ph.D., Hagop M. Kantarjian, M.D., Moshe Talpaz, M.D., Zeev Estrov, M.D.
Journal: Blood
Blood (2004) 104 (11): 1169.
https://doi.org/10.1182/blood.V104.11.1169.1169
Published: 2004
Journal Articles

Phase I Study Using Alternate Week Administration of the Farnesyl Transferase Inhibitor R115777 (Zarnestra™) in Patients with Myelodysplastic Syndrome.

Razelle Kurzrock, M.D., Srdan Verstovsek, M.D., John J. Wright, M.D., Susan R. Pilat, B.S.N., Jorge E. Cortes, M.D., Elihu H. Estey, M.D., Francis J. Giles, M.D., Miloslav Beran, M.D., Hagop M. Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1436.
https://doi.org/10.1182/blood.V104.11.1436.1436
Published: 2004
Journal Articles

Organic Arsenic Lipid Derivatives Are More Potent and Less Toxic Than Inorganic Arsenic Trioxide in Preclinical Testing.

Xiaodong Cheng, M.D., Mirna Golemovic, M.S., Francis Giles, M.D., Ralph Zingaro, Ph.D., Ming-Zhang Gao, Ph.D., Emil J. Freireich, M.D., Michael Andreeff, M.D., Ph.D., Hagop M. Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 1803.
https://doi.org/10.1182/blood.V104.11.1803.1803
Published: 2004
Journal Articles

Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS).

Gloria N. Mattiuzzi, M.D., Gladys Alvarado, M.D., Hagop M. Kantarjian, M.D., Srdan Verstovsek, M.D., Ph.D., Maria Cabanillas, M.D., Stefan Faderl, M.D., Joann T. Lim, PharmD, Francis Giles, M.D., Miloslav Beran, M.D., Ph.D, Susan O’Brien, M.D., Elihu H. Estey, M.D.
Journal: Blood
Blood (2004) 104 (11): 885.
https://doi.org/10.1182/blood.V104.11.885.885
Published: 2004